A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

计划入组 100 人 · 首次发布于 2023 年 10 月 12 日

A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)

计划入组 105 人 · 首次发布于 2026 年 8 月 4 日

Mesenchymal Stem Cells Derived Exosomes in Skin Rejuvenation

计划入组 20 人 · 首次发布于 2023 年 4 月 14 日

anti-LRP6 mAb

anti-LAG-3/anti-TIGIT mAb

anti-LRP6 agent (Novartis)

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

AGENCE REGIONALE DE SANTE DE LA REUNION

Reunion

VYVGART Achieves Primary Endpoint in Phase 3 Trial for AChR-Ab Seronegative Myasthenia Gravis

Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment

Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies